Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? - Wikidata - awgldk - TriplyDB

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

http://www.wikidata.org/entity/Q35776229

about

Management of pancreatic cancer in the elderly Desmoplasia and chemoresistance in pancreatic cancer New challenges in perioperative management of pancreatic cancer Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Neoadjuvant strategies for pancreatic cancer Therapeutic options for the management of pancreatic cancer.Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability Opportunities of improvement in the management of pancreatic and periampullary tumors.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Role of radiation therapy in the management of pancreatic cancer.Stereotactic body radiation therapy in pancreatic cancer: the new frontier.Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.Impact of Radiofrequency Ablation on Malignant Biliary Strictures: Results of a Collaborative Registry.Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival.Recent advances in the management of pancreatic adenocarcinoma.Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy

P2860

Q26774639-FADEBAF9-346F-4390-80B2-7797A62BDFA8 Q26864497-D0170F52-0A3F-447A-B6DF-0EAB57E05E5F Q28082422-E4DA0398-07D4-4926-8D71-08A4E2BB31B7 Q33751263-FEC27816-C2C1-4E6E-AB92-0338382788D6 Q33948343-250303D8-A8EE-480D-8D32-4D112E457D94 Q34093776-4B0168B1-D3C3-4CBF-9ABA-46BE507F809B Q36525188-C4D2B14B-AB98-4D24-AEA8-6D350F99118A Q36581449-85717FB7-56AB-4D68-A243-720F41510E91 Q36876409-34A9257B-06FE-47C9-A4C5-C0D20FEA6652 Q36879789-0849874B-5594-4BCA-9ADB-4B11DB5BEDDA Q37268613-A89228A7-EBB3-4C57-9B35-F5CD130EBDF9 Q38005349-AD2FFC46-B03A-4559-8152-6B92479F4682 Q38245676-0281DB3D-E67C-4B0C-9222-AA2A9B32FEDC Q38954668-F79ABCC2-8133-4116-9C31-E48B24F45D33 Q39030076-BA07F6BC-5E47-4FEB-BC78-010CA7019CE9 Q40165790-EBFC14BF-BAF4-4B10-ACAE-0411A35C9C90 Q41379167-54474164-54D6-4E68-B578-38567874AF97 Q41561293-344AD1E9-8E54-417A-9B69-763AA025FF23 Q50072347-46E79BAD-D997-4F50-92CA-D94F1ADFA9E4 Q53286113-B0F22821-4B20-48EB-B8EB-8407BBDD3C32 Q57174120-2E4BF63F-AB89-41DF-BB3A-3A3CC4D61BA8

P2860

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

http://www.wikidata.org/entity/Q35776229

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

@ast

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

@en

type

label

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

@ast

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

@en

prefLabel

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

@ast

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

@en

P1433

Q35776229-75B1E4E9-1C17-42EC-9205-1AA29E114A8E

P1476

Q35776229-13F26A53-1CE1-46EB-8DA1-6D91BB65A3D8

P2093

Q35776229-0EFF46E8-AE8C-42D6-9CA1-0CCE1D018BD2

Q35776229-17488643-47ED-457E-B1C7-9933AAC38EFC

Q35776229-3AF6A189-D1AD-4731-8577-2E98D6AC5499

Q35776229-9749F8FD-99FF-42A1-861B-3F8786CF74AD

Q35776229-AF49CE0F-0295-4097-8386-4F870868A307

Q35776229-D18C3AB7-652C-4257-A4CC-3696573ED270

P2860

Q35776229-067CB6B4-94E2-4B90-B2C0-4B61BC2651EF

Q35776229-10411674-D401-4D21-B8DF-705644386038

Q35776229-15E8B659-8A40-4DDB-B0F6-484829A8B53F

Q35776229-164CA131-3AE1-4ED9-AB0D-68D108BF4F52

Q35776229-27574EAC-86E5-4D7D-BEF8-A12E8ACDACA6

Q35776229-2E2AF51F-1A83-4CD1-A3F4-D237D6BB42D7

Q35776229-32759374-459E-40C6-AC5A-63D4A02FB3CD

Q35776229-37C37E23-FE94-4809-9E0D-CA2EFC32B371

Q35776229-38E7C93C-9B0B-452E-802B-A2B0C32A9E40

Q35776229-39C88877-4DED-4DE4-87F5-5CC474FFFBE6

P304

Q35776229-2231BAF9-44FB-4A7E-9FD9-F66FF38D35A8

P31

Q35776229-B06BFE5C-164E-4D14-A88F-9E613D717965

P356

Q35776229-06EAD99D-D457-4711-8C1E-7D5928B7154B

P433

Q35776229-FA5A6E2D-8019-427A-8565-78B77711490F

P478

Q35776229-5F8862A5-1503-434E-95D6-FD92FEB3FEF5

P50

Q35776229-6D5BE11F-561A-4FDF-8285-07FA9A007096

P577

Q35776229-683410DD-761B-4BD7-A450-3ED6AF46737B

P5875

Q35776229-6483B8BF-AA4C-4E38-B46B-4D6908DD0373

P698

Q35776229-9629F755-66DA-4BE6-A397-7E102C2E32E7

P932

Q35776229-1104E94E-A3AB-46AD-9A70-9C29F44DEB15

P356

THEONCOLOGIST.2011-0268

P1433

P1476

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

@en

P2093

Adeel Khan

http://www.w3.org/2001/XMLSchema#string

Andrea Wang-Gillam

http://www.w3.org/2001/XMLSchema#string

David Linehan

http://www.w3.org/2001/XMLSchema#string

Dengfeng Cao

http://www.w3.org/2001/XMLSchema#string

Eugene Chung

http://www.w3.org/2001/XMLSchema#string

Kian-Huat Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.

Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplina

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

P304

192-200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2011-0268

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Edgar Ben-Josef

P577

2012-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221752148

http://www.w3.org/2001/XMLSchema#string

P698

22250057

http://www.w3.org/2001/XMLSchema#string

P932

3286168

http://www.w3.org/2001/XMLSchema#string